Dystrogen Therapeutics Investigational Chimeric Cell Therapy DT-DEC01 for the Treatment of Duchene Muscular Dystrophy Shows Safety and Functional Improvements

Dystrogen Therapeutics, Corp. the leader in chimeric cell therapies, today announced positive results from an ongoing study conducted in Poland under a hospital exemption protocol of DT-DEC01 (Dystrophin expressing chimeric (DEC) cells), the Company’s investigational engineered cell therapy for Duchenne muscular dystrophy (DMD).